Literature DB >> 32501257

HIV and tuberculosis: The paradox of dual illnesses and the challenges of their fighting in the history.

Diana Canetti1, Niccolò Riccardi2, Mariano Martini3, Simone Villa4, Antonio Di Biagio5, Luigi Codecasa6, Antonella Castagna7, Ilaria Barberis8, Valentina Gazzaniga9, Giorgio Besozzi4.   

Abstract

Tuberculosis is an ancient infectious disease caused by the bacillus Mycobacterium tuberculosis that is still nowadays afflicting humans all over the world. It causes ill-health for 10 million people each year. Tuberculosis (TB) has been the leading cause of death from a single infectious agent, ranking above HIV/AIDS. In recent years, infection with HIV represents a major risk factor predisposing for infection and TB is the most common cause of AIDS-related death. Despite the treatment of HIV-associated TB has essentially retraced that recommended in HIV-negative cases, it has disclosed some additional challenges over the years. The association of delayed and missed diagnoses, logistic accidents and some well-known complications of HIV and TB treatment co-administration has contributed to 300,000 people living with HIV died from a preventable and curable disease like TB in 2017. The evaluation of new diagnostic and therapeutic approaches with the struggle to erase stigma are essential to successfully manage HIV-TB coinfection.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Year:  2020        PMID: 32501257     DOI: 10.1016/j.tube.2020.101921

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

1.  Impact of SARS-CoV-2 infection on tuberculosis outcome and follow-up in Italy during the first COVID-19 pandemic wave: a nationwide online survey.

Authors:  Diana Canetti; Roberta Maria Antonello; Laura Saderi; Mara Giro; Delia Goletti; Loredana Sarmati; Paola Rodari; Marialuisa Bocchino; Miriam Schirò; Niccolò Riccardi; Giovanni Sotgiu
Journal:  Infez Med       Date:  2022-09-01

2.  Pharmacophore modeling, docking and the integrated use of a ligand- and structure-based virtual screening approach for novel DNA gyrase inhibitors: synthetic and biological evaluation studies.

Authors:  Deepti Mathpal; Mukesh Masand; Anisha Thomas; Irfan Ahmad; Mohd Saeed; Gaffar Sarwar Zaman; Mehnaz Kamal; Talha Jawaid; Pramod K Sharma; Madan M Gupta; Santosh Kumar; Swayam Prakash Srivastava; Vishal M Balaramnavar
Journal:  RSC Adv       Date:  2021-10-25       Impact factor: 4.036

3.  Drug Resistance Pattern of M. tuberculosis Complex in Oromia Region of Ethiopia.

Authors:  Hussien Bedru; Melaku Fikru; Wardofa Niguse; Aman Jemal; Garoma Getinet; Ameni Gobena; Awraris Hailu; Sandy Peter
Journal:  Infect Drug Resist       Date:  2021-05-04       Impact factor: 4.003

4.  Rv3737 is required for Mycobacterium tuberculosis growth in vitro and in vivo and correlates with bacterial load and disease severity in human tuberculosis.

Authors:  Qing Li; Zhangli Peng; Xuefeng Fu; Hong Wang; Zhaoliang Zhao; Yu Pang; Ling Chen
Journal:  BMC Infect Dis       Date:  2022-03-14       Impact factor: 3.090

5.  HIV-related non-Hodgkin lymphomas affecting the oral cavity: a clinicopathologic study of 11 cases.

Authors:  D-C Uchôa; F-S Pontes; L-L Souza; G-S Santos; A-C Prado-Ribeiro; T-B Brandão; L-R Oliveira; C-C Gomes; A-R Santos-Silva; F-P Fonseca; O-P Almeida; H-A Pontes
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-03-01

Review 6.  Tuberculosis: a timeless challenge for medicine.

Authors:  E Armocida; M Martini
Journal:  J Prev Med Hyg       Date:  2020-07-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.